Core Insights - Lunai Bioworks Inc.'s subsidiary BioSymetrics Inc. has received a Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH) [1] - The grant will be used in collaboration with Brigham and Women's Hospital to develop a platform that integrates artificial intelligence and in vivo zebrafish screening [1] - The project aims to accelerate drug discovery for Alcohol Use Disorder (AUD), which affects over 19 million Americans and is linked to oncologic and neurologic disorders [1] Company Summary - BioSymetrics Inc. is focused on innovative drug discovery methods utilizing advanced technologies [1] - The partnership with Brigham and Women's Hospital highlights the company's commitment to addressing significant health issues [1] Industry Context - Alcohol Use Disorder (AUD) is a prevalent condition in the U.S., impacting millions and contributing to serious health complications [1] - The integration of artificial intelligence in drug discovery represents a growing trend in the pharmaceutical industry, aiming to enhance efficiency and effectiveness [1]
Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics